Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Protein Degradation Therapy Market CAGR Outlook And Future Development
The protein degradation therapy market size has experienced significant expansion recently. It is projected to grow from $1.25 billion in 2025 to $1.35 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.1%. This historic growth can be attributed to several factors, including advancements in molecular biology research, the expansion of targeted cancer therapies, an increased understanding of protein dysfunction in diseases, early-stage clinical successes, and growing venture capital funding in biotech.
The protein degradation therapy market is anticipated to experience substantial expansion in the coming years. Its valuation is projected to reach $1.83 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.8%. This expansion during the forecast period is propelled by factors such as the increasing need for new cancer treatments, growing investments in precision oncology, the broadening of protein degradation platforms, heightened clinical trial engagements, and greater regulatory backing for pioneering therapeutic solutions. Key developments anticipated in this period include the accelerated creation of targeted protein degraders, a sharpened emphasis on oncological uses, increased capital flow into PROTAC-based treatments, the enlargement of candidate pipelines in clinical stages, and improved partnerships between pharmaceutical and biotechnology companies.
Get A Free Sample Report With In-Depth Market Insights:
Protein Degradation Therapy Market Development Factors: What’s Supporting Demand?
The increasing impact of cancer is anticipated to fuel the expansion of the protein degradation therapy market moving ahead. Cancer encompasses various conditions characterized by the unchecked multiplication and spread of atypical cells throughout the body. The incidence of cancer is increasing chiefly due to multiple factors, notably the expanding elderly demographic. Furthermore, lifestyle elements like tobacco use, unhealthy eating habits, insufficient exercise, and increasing levels of obesity have elevated the likelihood of developing diverse cancers. The necessity for protein degradation therapy in cancer treatment stems from its ability to target and eradicate particular proteins crucial for cancer progression and survival, potentially surmounting resistance to conventional therapies. For example, in February 2024, a report released by the World Health Organization, an intergovernmental entity based in Switzerland, projected that more than 35 million new cancer cases are expected by 2050, signifying a 77% surge from the approximately 20 million cases in 2022. Additionally, nations with a high Human Development Index (HDI) are forecasted to experience the most substantial rise in absolute figures, with an extra 4.8 million new cases anticipated in 2050 when contrasted with 2022 projections. Consequently, the expanding challenge of cancer is propelling the advancement of the protein degradation therapy market.
Protein Degradation Therapy Market Segments: Where Is Growth Concentrated?
The protein degradation therapy market covered in this report is segmented –
1) By Type: Bavdegalutamide (ARV – 110), Vepdegestrant (ARV – 471)
2) By Application: Oncology, Neurodegenerative Diseases, Infectious Diseases, Other Applications
3) By End-User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutes
Subsegments:
1) By Bavdegalutamide (ARV-110): Androgen Receptor Degraders, Prostate Cancer Therapy
2) By Vepdegestrant (ARV-471): Estrogen Receptor Degraders, Breast Cancer Therapy
Protein Degradation Therapy Market Transformation Trends: What Innovations Are Driving Change?
Leading companies in the protein degradation therapy market are increasingly adopting a strategic partnership approach to cultivate advanced therapies, capitalize on complementary specialized knowledge, share available assets, and accelerate both the discovery and subsequent development of novel drug candidates aimed at disease-contributing proteins. These strategic alliances involve organizations leveraging each other’s strengths and resources to achieve mutual advantages and shared accomplishments. For example, in February 2024, Arvinas, a U.S.-based biotechnology company, launched its inaugural oral PROTAC degrader (ARV-102), engineered to permeate the blood-brain barrier and target LRRK2 for applications in neurodegenerative diseases. The ARV-102 molecule is characterized by oral bioavailability, a brain-penetrant profile, and strong specificity for LRRK2. Such innovations enhance company pipelines by enabling the treatment of targets previously considered undruggable, although difficulties persist regarding long-term safety, manufacturing intricacies, and the optimization of pharmacokinetics due to the molecule’s considerable size.
Protein Degradation Therapy Market Key Participants And Competitive Landscape
Major companies operating in the protein degradation therapy market are Relay Therapeutics, Arvinas Holding Company LLC, Kymera Therapeutics, Nurix Therapeutics, Vividion Therapeutics, Mission Therapeutics Ltd., C4 Therapeutics Inc., Cullgen Inc., Frontier Medicines, Foghorn Therapeutics, Aileron Therapeutics, Ribometrix Inc., Nimbus Therapeutics, Jnana Therapeutics, KSQ Therapeutics, Stoke Therapeutics, Flare Therapeutics, Accent Therapeutics, Monte Rosa Therapeutics, Lycia Therapeutics, Dialectic Therapeutics, Amphista Therapeutics, Biotheryx Inc., Cedilla Therapeutics, Dewpoint Therapeutics Inc
View The Full Protein Degradation Therapy Market Report:
Protein Degradation Therapy Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the protein degradation therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the protein degradation therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model